Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P910056/S065

enVista Aspire Hydrophobic Acrylic Intraocular Lens (IOL)

Bausch + Lomb, Inc. · Decision date Sep 29, 2026

MEDTECHLEDGER EXPLANATIONP910056/S065

What did the FDA decide?

FDA database entry P910056/S065 records a 30-day notice for the enVista Aspire hydrophobic acrylic intraocular lens, Models EA and ETA, submitted by Bausch & Lomb, Inc. The stated change is from a manual to an automatic process in the secondary packaging system for these IOLs.

The supplement type is a process change involving the manufacturer, sterilizer, packager, or supplier. The decision is OK30, dated 2026-09-29. The database does not state which specific packaging steps are automated, what equipment is involved, or any effect on sterility, labeling, or device performance.

FDA approval order statement

change from a manual to an automatic process in the secondary packaging system of the enVista Aspire Intraocular lenses (IOLs), Models EA and ETA
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Sep 29, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P910056/S065
Regulatory pathway
PMA supplement
Product code
HQL
Decision code
OK30
Decision date
Sep 29, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: intraocular lens.

Product code
HQL
FDA device class
3

For the original device and its historical approval scope, see PMA P910056. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P910056 · Original PMA

    SOFLEX UV-ABSORBING SILICONE POSTERIOR CHAMBER INTRAOCULAR LENS

  2. P910056/S063 · Related supplement

    enVista hydrophobic acrylic intraocular lens

  3. P910056/S065 received

    Application receipt date recorded by FDA.

  4. P910056/S065 · FDA decision

    30-Day Notice

  5. P910056/S064 · Related supplement

    enVista Hydrophobic Acrylic Intraocular Lens

  6. P910056/S066 · Related supplement

    enVista Hydrophobic Acrylic Intraocular Lens

  7. P910056/S067 · Related supplement

    enVista Hydrophobic Acrylic Intraocular Lens

Timeline entries are records held by MedtechLedger for P910056. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P910056

Product / regulatory recordCompanyPathwayDecision dateSource
Bausch + Lomb, Inc.PMA approvalJan 17, 1992FDA
Bausch + Lomb, Inc.PMA supplementSep 3, 2026FDA
Bausch + Lomb, Inc.PMA supplementSep 30, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 14, 2026FDA
Bausch + Lomb, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Other records with product code HQL

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Bausch + Lomb, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
50 Technology Dr., Irvine, CA, 92618

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records